SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

Crudes sharp rally is drawing attention amid reports and fears of escalating Middle East conflict, tanker attacks near the Strait of Hormuz, and threats to regional oil flows. Traders are split between a supply-disruption-driven bullish view and expectations that diplomacy, additional supply, or profit-taking could reverse the move.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention amid a volatile tech rebound, with traders split over whether repeated V-shaped recoveries reflect durable dip-buying or a bull trap. Rising oil prices tied to Middle East tensions and doubts about AI infrastructure spending weigh on sentiment, while upcoming megacap earnings are seen as a test for the bounce.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStops warrant-expiration deadline is dominating discussion: holders are weighing whether the shares can reach the warrants exercise price before they expire, while traders debate whether they will lapse worthless or be extended. The uncertainty has fueled frustration over the recent pullback and Cohens actions, alongside bullish speculation that he could still provide a catalyst and bearish views that expiration would remove potential dilution.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

Hot inflation readings and elevated Treasury yields are weighing on rate-sensitive small caps, with traders focused on Fed tightening risks and IWMs technical weakness. The discussion is split between bearish bets on further declines and buyers looking for an oversold bounce near support.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

A prolonged post-IPO selloff is dominating discussion, with traders citing upcoming lockup expirations and insider share sales as added supply pressure, alongside a TD Cowen price-target cut and concerns about valuation, growth, and customer concentration. Bears see further downside risk, while some bulls argue the shares are oversold and Cerebrass AI-chip technology offers long-term potential.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

CIFR is drawing attention after a steep selloff that traders widely blame on its convertible-note financing and expected share dilution, alongside broader weakness in AI/data-center stocks and concerns about debt and financing costs. The reaction is sharply divided: many holders criticize management and fear further losses, while some see the decline as an oversold pullback and remain bullish on its AI infrastructure contracts.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celesticas sharp, volatile pullback is being linked by traders to the dilutive $3 billion share offering priced at $310, with many debating whether the weakness is overdone. Bullish traders argue the capital supports expansion for AI and data-center demand and point to the raised outlook, while others remain focused on downside risk and key support levels.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention amid a sharp AI-infrastructure selloff and a relief bounce, with traders split on whether the rebound signals stabilization or another short-lived rally. Concerns about neocloud financing and capital spendingheightened by CoreWeaves debt worriescompete with the bullish view that Nebius is better positioned and could capture demand from struggling providers.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves sharp selloff is being tied mainly to concerns about its heavy debt, financing costs and ability to fund AI infrastructure expansion, amid broader weakness in neocloud stocks. Bears warn of dilution or default, while bulls cite its contracted backlog, Nvidia ties and ARKs buying; the Goldman upgrades failure to sustain a rally underscores the divide.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale shares are under pressure after UBS downgraded the stock to Sell, citing long commercialization timelines and a lack of firm customer commitments; traders debate whether the selloff reflects those execution risks or is an overreaction, with some bulls still backing the long-term nuclear-power thesis. The decline also fits broader weakness in speculative nuclear stocks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zura Bio to Participate in the Cantor Global Healthcare Conference

Zura Bio Limited (Nasdaq: ZURA) (Zura), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that members of its management team will...

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zura Bio Limited (Nasdaq: ZURA) (Zura or the Company), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on August 20, 2026, the...

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

Zura Bio Limited (Nasdaq: ZURA) (Zura), a clinicalstage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced financial results for the second quarter...

Analyst Sees Multi-Billion-Dollar Sales Potential for Zura Bio's Lead Therapy

William Blair starts Zura Bio (NASDAQ: ZURA) at Outperform, citing tibulizumab's multibillion-dollar potential in autoimmune disease.read more...

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

Zura Bio Limited (Nasdaq: ZURA) (Zura), a clinical stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced several tibulizumab program updates. Zura...

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zura Bio Limited (Nasdaq: ZURA) (Zura or the Company), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious...

Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer

Zura Bio Limited (Nasdaq: ZURA) (Zura), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and...

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

Zura Bio Limited (Nasdaq: ZURA) (Zura or the Company), a clinicalstage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious...

Zura Bio (ZURA) to Release Earnings on Thursday

Zura Bio (NASDAQ:ZURA) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-zura-bio-limited-stock...

Zura Bio Ltd. is a clinical-stage, multi-asset immunology company, which engages in the development of novel medicines for immune disorders. It focuses on the development of ZB-168, a treatment for Alopecia Areata and other inflammatory diseases. The company was founded by Someit Sidhu on January 18, 2022 and is headquartered in Henderson, NV.

Zura Bio Ltd - Ordinary Shares - Class A

Novartis Drug Shows Improvement In Sjögren's Disease In Late-Stage Trials: Analyst Deems Data Positive For Zura Bio As Well

Equity

Bullish Sentiment

Novartis (NVS) on Monday announced positive results from its late-stage trials evaluating its investigational drug Ianalumab in adults with active Sjögren's disease.Ianalumab is a novel fully human monoclonal antibody being investigated for its potential to treat various B-cell-driven autoimmune diseases. The drug’s mechanism of action targets B cells in two ways: combining B cell depletion and interruption of BAFF-R-mediated signals of B cell function and survival.Guggenheim said the positive updates give evidence that BAFF-signaling disruption and B cell depletion are "a valid approach" for hard-to-treat autoimmune diseases, which has a positive read-through for Zura Bio (ZURA). Shares of <a href="https://stocktwits.com/symbol/ZURA">Zura</a>, which Guggenheim deems "significantly undervalued," traded 3% higher at the time of writing.Novartis <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novartis.com/news/media-releases/novartis-announces-both-ianalumab-phase-iii-clinical-trials-met-primary-endpoint-patients-sjogrens-disease">said</a> that its two late-stage trials for Sjögren's disease met the primary endpoint of demonstrating statistically significant improvements in disease activity. Novartis now sees the potential for the drug to become the first and only targeted treatment approved for patients with the disease.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVS">Novartis</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:625/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_11_at_12_02_03_PM_png_fdf22daf95.webp" alt="NVO's Sentiment Meter and Message Volume as of 12:02 p.m. ET on Aug. 11, 2025 | Source: Stocktwits" width="625" height="61"><figcaption>NVO's Sentiment Meter and Message Volume as of 12:02 p.m. ET on Aug. 11, 2025 | Source: Stocktwits</figcaption></figure>Sjögren’s disease is a systemic, chronic autoimmune disorder that causes inflammation and tissue damage, impacting the entire body. It primarily affects exocrine glands, leading to excessive dryness, with over 90% of patients experiencing dry eyes and dry mouth.“These Phase III studies mark a significant milestone. We look forward to engaging with health authorities to discuss these findings in the near future,” said Shreeram Aradhye, President of Development and Chief Medical Officer at Novartis.Ianalumab was well tolerated and demonstrated a favorable safety profile in Sjögren's disease, the company said, while adding that it plans to submit the drug to health authorities globally.NYSE-listed shares of the company traded 1% higher at the time of writing.Ianalumab originated from Novartis’ early collaboration with MorphoSys AG, a company which it later acquired in 2024. In clinical trials, Ianalumab showed promising efficacy and a favorable safety profile in Sjögren’s disease, systemic lupus erythematosus, and immune thrombocytopenia.While NVS shares are up by 21% this year, ZURA is down 42%.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/avantor-responds-to-activist-investor-engine-capital-letter/chru67IRde5">Avantor Responds To Activist Investor Engine Capital’s Letter: ‘Acting With Urgency To Strengthen Growth’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Novartis now sees the potential for the drug to become the first and only targeted treatment approved for patients with the disease.

Novartis AG

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$3.81
Prev Close	$3.88
Open	$3.91
Dividend Yield	0.00%
50-Day Moving Average	$4.99
Beta	1.60
Avg. Volume	1.74M
PE Ratio	-3.03

52-Week High	$7.44
52-Week Low	$3.15
Market Capitalization	$371.82M
EPS (Annual)	-$1.06
Price to Book	1.84
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

ZURA Fundamentals